Drug Shortage Report for ACYCLOVIR SODIUM INJECTION
| Report ID | 130355 |
| Drug Identification Number | 02236916 |
| Brand name | ACYCLOVIR SODIUM INJECTION |
| Common or Proper name | Acyclovir Sodium Injection |
| Company Name | PFIZER CANADA ULC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | ACYCLOVIR |
| Strength(s) | 25MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 20mL vial |
| ATC code | J05AB |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2021-02-05 |
| Estimated end date | |
| Actual end date | 2021-04-22 |
| Shortage status | Resolved |
| Updated date | 2021-04-23 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v21 | 2021-04-23 | English | Compare |
| v20 | 2021-04-22 | French | Compare |
| v19 | 2021-04-22 | English | Compare |
| v18 | 2021-04-13 | French | Compare |
| v17 | 2021-04-13 | English | Compare |
| v16 | 2021-03-24 | French | Compare |
| v15 | 2021-03-24 | English | Compare |
| v14 | 2021-03-03 | French | Compare |
| v13 | 2021-03-03 | English | Compare |
| v12 | 2021-02-16 | French | Compare |
| v11 | 2021-02-16 | English | Compare |
| v10 | 2021-02-06 | English | Compare |
| v9 | 2021-02-05 | French | Compare |
| v8 | 2021-02-05 | English | Compare |
| v7 | 2021-01-26 | French | Compare |
| v6 | 2021-01-26 | English | Compare |
| v5 | 2021-01-18 | French | Compare |
| v4 | 2021-01-18 | English | Compare |
| v3 | 2021-01-16 | English | Compare |
| v2 | 2020-12-17 | French | Compare |